LncRNA HOXB-AS3 binding to PTBP1 protein regulates lipid metabolism by targeting SREBP1 in endometrioid carcinoma

Zhou, Qing; Kong, Deshui; Li, Wenzhi; Shi, Zhengzheng; Liu, Yao; Sun, Rui; Ma, Xiaohong; Qiu, Chunping; Liu, Zhiming; Hou, Yixin; Jiang, Jie

doi:10.1016/j.lfs.2023.121512

Cited by 5 publications

(14 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent studies, aberrant expression of the HOXB-AS3 RNA has been found in liver cancer 47 , 49 , lung cancer 43 , ovarian cancer 41 , 44 , endometrial cancer 42 , 48 , 51 , and acute myeloid leukemia 45 , 46 , 50 . And at the protein expression level, abnormal expression of the HOXB-AS3 micro-peptide has been reported in oral squamous cell carcinoma 52 and colon cancer 40 ( Table 1 ).…”

Section: Promising Clinical Biomarker In Human Cancermentioning

confidence: 99%

“…Currently most studies have focused on the functional significance of lncRNA HOXB-AS3 across various cancer types, encompassing lung cancer 43 , liver cancer 47 , 49 , ovarian cancer 41 , 44 , endometrial cancer 42 , 48 , 51 , and acute myeloid leukemia 45 , 46 , 50 . The regulatory mechanisms of lncRNA HOXB-AS3 in these tumors are delineated in Figure 7 .…”

Section: Role and Mechanisms Of Hoxb-as3 In Cancermentioning

confidence: 99%

“…Ovarian cancer and endometrial carcinoma are the two most common gynecologic tumors, and the elevated expression of lncRNA HOXB-AS3 has been observed in both cancer specimens and cancer cell lines associated with these two cancers 41 , 42 , 44 , 48 . In ovarian cancer, elevated levels of HOXB-AS3 indicated an adverse prognosis 41 , 44 , and HOXB-AS3 overexpression is linked to higher histological grade, advanced FIGO stage, and lymph node metastasis in patients 44 .…”

Section: Role and Mechanisms Of Hoxb-as3 In Cancermentioning

confidence: 99%

“…HOXB-AS3 overexpression could promote EC progression 42 . Furthermore, research also unveiled the regulatory role of HOXB-AS3 on tumor development, involving multiple pathways 43 , 44 , 47 , 48 . HOXB-AS3 demonstrates promising potential as an oncological biomarker and therapeutic target in human malignant disorders.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A concise review of the regulatory, diagnostic, and prognostic implications of HOXB-AS3 in tumors

Wu,

Ye,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Recent studies have reported that HOXB-AS3 (HOXB Cluster Antisense RNA 3) is an intriguing molecule with dual functionality as a long noncoding RNA (lncRNA) and putative coding peptide in tumorigenesis and progression. The significant expression alterations of HOXB-AS3 were detected in diverse cancer types and closely correlated with clinical stage and patient survival. Furthermore, HOXB-AS3 was involved in a spectrum of biological processes in solid tumors and hematological malignancies, such as stemness, lipid metabolism, migration, invasion, and tumor growth. This review comprehensively analyzes its clinical relevance for diagnosis and prognosis across human tumors and summarizes its functional role and regulatory mechanisms in different malignant tumors, including liver cancer, acute myeloid leukemia, ovarian cancer, lung cancer, endometrial carcinoma, colon cancer, and oral squamous cell carcinoma. Overall, HOXB-AS3 emerges as a promising biomarker and novel therapeutic target in multiple human tumors.

show abstract

Section: Promising Clinical Biomarker In Human Cancermentioning

confidence: 99%

Section: Role and Mechanisms Of Hoxb-as3 In Cancermentioning

confidence: 99%

Section: Role and Mechanisms Of Hoxb-as3 In Cancermentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A concise review of the regulatory, diagnostic, and prognostic implications of HOXB-AS3 in tumors

Wu,

Ye,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

show abstract

“…[ 167 ] Moreover, lncRNA HOXB‐AS3 have been shown to co‐regulate the expression of SREBP1 with RNA‐binding protein‐PTBP1 via direct binding, which further promotes lipid metabolism and proliferation of endometrial cancer (EC). [ 168 ] Another RNA‐binding protein HuR has also been found to co‐regulate the mRNA stability of SREBP1 with circMyc and degradation of Myc with circREOS . CircMyc (hsa_circ_00 85 533) has been found to be remarkably upregulated in triple‑negative breast cancer.…”

Section: Lncrnas‐circrnas Regulate the Rewiring Of Lipid Metabolism I...mentioning

confidence: 99%

LncRNAs‐circRNAs as Rising Epigenetic Binary Superstars in Regulating Lipid Metabolic Reprogramming of Cancers

Liu,

Jiao,

Zhao

et al. 2023

Advanced Science

View full text Add to dashboard Cite

As one of novel hallmarks of cancer, lipid metabolic reprogramming has recently been becoming fascinating and widely studied. Lipid metabolic reprogramming in cancer is shown to support carcinogenesis, progression, distal metastasis, and chemotherapy resistance by generating ATP, biosynthesizing macromolecules, and maintaining appropriate redox status. Notably, increasing evidence confirms that lipid metabolic reprogramming is under the control of dysregulated non‐coding RNAs in cancer, especially lncRNAs and circRNAs. This review highlights the present research findings on the aberrantly expressed lncRNAs and circRNAs involved in the lipid metabolic reprogramming of cancer. Emphasis is placed on their regulatory targets in lipid metabolic reprogramming and associated mechanisms, including the clinical relevance in cancer through lipid metabolism modulation. Such insights will be pivotal in identifying new theranostic targets and treatment strategies for cancer patients afflicted with lipid metabolic reprogramming.

show abstract

Signature identification based on immunogenic cell death-related lncRNAs to predict the prognosis and immune activity of patients with endometrial carcinoma

Yao,

Zhang,

Wei

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

Background Endometrial carcinoma (EC) is one of the most prevalent gynecologic malignancies and requires further classification for treatment and prognosis. Long non-coding RNAs (lncRNAs) and immunogenic cell death (ICD) play a critical role in tumor progression. Nevertheless, the role of lncRNAs in ICD in EC remains unclear. This study aimed to explore the role of ICD related-lncRNAs in EC via bioinformatics and establish a prognostic risk model based on the ICD-related lncRNAs. We also explored immune infiltration and immune cell function across prognostic groups and made treatment recommendations. Methods A total of 552 EC samples and clinical data of 548 EC patients were extracted from The Cancer Genome Atlas (TCGA) database and University of California Santa Cruz (UCSC) Xena, respectively. A prognostic-related feature and risk model was developed using the least absolute shrinkage and selection operator (LASSO). Subtypes were classified with consensus cluster analysis and validated with t-Distributed Stochastic Neighbor Embedding (tSNE). Kaplan-Meier analysis was conducted to assess differences in survival. Infiltration by immune cells was estimated by single sample gene set enrichment analysis (ssGSEA), Tumor IMmune Estimation Resource (TIMER) algorithm. Quantitative polymerase chain reaction (qPCR) was used to detect lncRNAs expression in clinical samples and cell lines. A series of studies was conducted in vitro and in vivo to examine the effects of knockdown or overexpression of lncRNAs on ICD. Results In total, 16 ICD-related lncRNAs with prognostic values were identified. Using SCARNA9, FAM198B-AS1, FKBP14-AS1, FBXO30-DT, LINC01943, and AL161431.1 as risk model, their predictive accuracy and discrimination were assessed. We divided EC patients into high-risk and low-risk groups. The analysis showed that the risk model was an independent prognostic factor. The prognosis of the high- and low-risk groups was different, and the overall survival (OS) of the high-risk group was lower. The low-risk group had higher immune cell infiltration and immune scores. Consensus clustering analysis divided the samples into four subtypes, of which cluster 4 had higher immune cell infiltration and immune scores. Conclusions A prognostic signature composed of six ICD related-lncRNAs in EC was established, and a risk model based on this signature can be used to predict the prognosis of patients with EC.

show abstract

LncRNA HOXB-AS3 binding to PTBP1 protein regulates lipid metabolism by targeting SREBP1 in endometrioid carcinoma

Cited by 5 publications

References 52 publications

A concise review of the regulatory, diagnostic, and prognostic implications of HOXB-AS3 in tumors

A concise review of the regulatory, diagnostic, and prognostic implications of HOXB-AS3 in tumors

LncRNAs‐circRNAs as Rising Epigenetic Binary Superstars in Regulating Lipid Metabolic Reprogramming of Cancers

Signature identification based on immunogenic cell death-related lncRNAs to predict the prognosis and immune activity of patients with endometrial carcinoma

Contact Info

Product

Resources

About